Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

May 5, 2025

WATERTOWN, Mass., May 5, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)...

August 14, 2025

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

WATERTOWN, Mass., August 14, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)... Read More

July 9, 2025

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

WATERTOWN, Mass., July 9, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)... Read More

June 12, 2025

Werewolf Therapeutics to Participate in the BIO International Convention

WATERTOWN, Mass., June 12, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)... Read More

Share this article: